IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), is pleased to announce that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit, which is set to be held in Boston, MA, June 7-9th, 2022.
In the rapidly growing field of gene therapy, companies and institutions believe that creating patient-centric gene therapy programs is eminent to successful development. The 2nd Annual Gene Therapy Patient Engagement Summit unites patient advocacy groups, engagement leaders and the patients themselves to provide insight and honest discussions.
During the three-day event, presentations will be held on a variety of topics, including how to manage expectations of gene therapy across stakeholders, incorporating the latest regulatory guidelines on patient input, designing and implementing meaningful clinical trials, tackling education and misconceptions in gene therapy and engaging in early development with patient groups. Presenters will include the likes of Spark Therapeutics, Ultragenyx, FDA, Global Genes andCRISPR Therapeutics.
Separately, and in addition to the coverage provided by Hanson Wade and BioMedWire, IBN is set to provide social media coverage of the event. Collectively among its 50+ brands, IBN reaches more than 2 million likes and followers across various social networking platforms.
“Our team is excited to be working with Hanson Wade as we raise the visibility of the 2nd Annual Gene Therapy Patient Engagement Summit,” said Jonathan Keim, Director of Communications. “Hanson Wade has gained a well-deserved reputation as an informational leader in the space. We look forward to featuring the innovations taking place in gene therapy programs where the patient’s experience and voice are vital to the industry’s advancements.”
For additional details about the 2nd Annual Gene Therapy Patient Engagement Summit, visit https://genetherapy-patient-engagement.com
IBN consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.